The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / COVID-19 Risks & Treatment for Patients with Rheumatic Disease

COVID-19 Risks & Treatment for Patients with Rheumatic Disease

December 4, 2020 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—On March 12, a gastroenterologist tweeted about a registry that had been started to track outcomes for patients with gastrointestinal disorders who’d been diagnosed with COVID-19. A rheumatologist reposted it, asking whether such a registry had been started in rheumatology.

You Might Also Like
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
  • COVID-19: Most Individuals with Rheumatic Disease Recover
  • Respiratory Failure More Common in COVID-19 Patients with Rheumatic Disease
Also By This Author
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App

It hadn’t. But just two weeks later, the registry—now known as the Global Rheumatology Alliance registry—had been launched, and more than 20 cases were reported in the first 24 hours.

Dr. Grainger

Global Rheumatology Alliance
The quick action, said Rebecca Grainger, MBChB, PhD, associate professor of rheumatology at the University of Otago, New Zealand, in a talk at ACR Convergence, is a dramatic example of how the rheumatology community worldwide has come together during the pandemic.

Since then, data collected through the registry has helped point the way forward, identifying suitable treatment options and vulnerable populations, Dr. Grainger said. The Alliance, now a section of the ACR, includes data and support from approximately 300 professional and patient organizations, including the European League Against Rheumatism.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

From early data—about 600 cases from March and April—researchers found that being 65 years or older was associated with hospitalization from COVID-19, with an odds ratio (OR) of 2.55, as were hypertension, lung disease, diabetes and chronic kidney or end-stage renal disease (OR≈1.83–3.07). A daily prednisone dose of 10 mg or more per day was also associated with hospitalization (OR=2.12). Treatment with a biological or targeted synthetic disease-modifying anti-rheumatic drug (DMARD) was associated with a lower hospitalization risk (OR=0.46).

Researchers have also looked at disparities in outcomes, using U.S. data from about 1,300 cases from March to August. They’ve found that being Black (OR=2.8), Asian (OR=2.7) or Latinx (OR=1.7) is associated with higher risk of hospitalization. Being Latinx is also associated with a higher risk of requiring ventilation support (OR=3.3).

Based on about 3,300 cases from March to July, researchers found the risk of death from COVID-19 is associated with increased age, male sex, moderate to high rheumatic disease activity and, in the case of patients with rheumatoid arthritis (RA), ever having smoked.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Two studies based on Alliance data have already been published, with a third publication expected soon, Dr. Grainger noted.1,2

“As rheumatologists, we are in a strong position to advocate [for our patients],” she said. “We must advocate for measures that protect people with rheumatic disease, in particular people from racial and ethnic minorities. We must advocate for information, reduced infection risk” and more widespread testing.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, COVID-19, COVID-19 Global Rheumatology Alliance, Global Rheumatology Alliance

You Might Also Like:
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
  • COVID-19: Most Individuals with Rheumatic Disease Recover
  • Respiratory Failure More Common in COVID-19 Patients with Rheumatic Disease
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)